1. Home
  2. GLND vs CRDF Comparison

GLND vs CRDF Comparison

Compare GLND & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GLND

Greenland Energy Company Common Stock

N/A

Current Price

$1.40

Market Cap

101.0M

Sector

Energy

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.04

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLND
CRDF
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.0M
86.8M
IPO Year
2026
2012

Fundamental Metrics

Financial Performance
Metric
GLND
CRDF
Price
$1.40
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
1.6M
699.6K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$1.10
$0.76
52 Week High
$12.80
$3.31

Technical Indicators

Market Signals
Indicator
GLND
CRDF
Relative Strength Index (RSI) 36.08 54.44
Support Level $1.10 $0.87
Resistance Level $2.44 $1.13
Average True Range (ATR) 0.10 0.07
MACD 0.02 0.02
Stochastic Oscillator 65.26 77.83

Price Performance

Historical Comparison
GLND
CRDF

About GLND Greenland Energy Company Common Stock

Greenland Energy Co is a Texas energy resources company focused on unlocking Greenland's vast hydrocarbon potential through the application of modern exploration technologies. It holds exclusive licenses to over 2-million acre area in the Jameson Land Basin, where its licenses cover the majority of the basin. The business model for the company is based on exploration and resource development in the frontier basins of Greenland. The company's primary focus is drilling the first wells on the project to conduct the necessary exploration, appraisal and evaluation.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: